OM
RCKT icon

Opaleye Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Opaleye Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
1,000,000
+45,000
+5% +$150K 0.31% 41
2026
Q1 		$3.42M Hold
955,000
– – 0.45% 39
2025
Q4 		$3.35M Buy
+955,000
New +$3.27M 0.44% 37
2018
Q1 		– Sell
-450,500
Closed -$4.7M – 43
2017
Q4 		$4.7M Hold
450,500
– – 1.51% 21
2017
Q3 		$3.21M Buy
+450,500
New +$2.06M 1.13% 26

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Opaleye Management's RCKT Position: Q2 2026 in Review

Opaleye Management increased its Rocket Pharmaceuticals (RCKT) stake by 4.7% in Q2 2026, buying an estimated $150K and bringing the position to 1,000,000 shares worth $3.42M. The position accounts for 0.31% of the portfolio, ranked #41.

Opaleye Management first reported a position in RCKT in Q3 2017 and has held it in 5 quarters since. The position peaked at $4.7M in Q4 2017. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Opaleye Management held 1,000,000 shares of Rocket Pharmaceuticals worth $3.42M as of Q2 2026.
  • Opaleye Management bought 45,000 Rocket Pharmaceuticals shares in Q2 2026, an estimated $150K.
  • Rocket Pharmaceuticals made up 0.31% of Opaleye Management's portfolio in Q2 2026, its #41 holding.
  • Opaleye Management first reported a position in Rocket Pharmaceuticals in Q3 2017 and has held it in 5 quarters since.
  • Opaleye Management's Rocket Pharmaceuticals position peaked at $4.7M in Q4 2017.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.